June 2025 Volume 21, Issue 2
Volume 21, Issue 2 | June 2025
June 2025
In this Issue
Mass Spectrometry
Sniffing out tuberculosis in human breath
Scientists are turning to breath samples as a way to detect tuberculosis economically and conveniently.
Mapping proteins to reveal secret drug binding pockets
Chemoproteomic tools are yielding early drug candidates for previously undruggable proteins.
Annihilating PFAS with an AI-designed enzyme
Using artificial intelligence and machine learning, a team of researchers engineered an enzyme to degrade toxic PFAS molecules — and they’re only in high school.Gene Editing
Gene-edited stem cells aim to reverse rheumatoid arthritis
A new approach for gene editing will get its shot in a common and chronic autoimmune disorder.
Epigenetic editing expands the reach of gene therapy
Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms.
Curing rare childhood blindness with a special gene therapy
Via a unique regulatory route in the UK, scientists found that a gene therapy restored vision in young kids with a very rare and severe retinal dystrophy.Antibody Drugs
To fight HIV, antibodies boost the immune system
HIV is incurable because it hides in latently infected cells. Researchers are hoping to change that — and prevent new infections — with the use of antibodies.
Ending allergies at the source with a pair of antibody drugs
With new insight into IgE biology, a new, two-pronged strategy for eliminating the pathogenic immune cells that lead to allergies emerges.Ophthamology
An anti-amyloid drug for blindness
Galimedix has recruited people with dry AMD to test the efficacy of their drug, which disrupts the same toxic beta-amyloid oligomers implicated in Alzheimer’s disease.Editor's Insight
